Articles related to OVARIAN CANCER

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Mirvetuximab soravtansine represents a pivotal shift in treating platinum-resistant ovarian cancer, demonstrating not only improved survival outcomes but also a higher response rate compared to standard chemotherapy.

Explore the transformative potential of antibody-drug conjugates (ADCs) in cancer therapy, offering targeted treatments with reduced side effects. Recent approvals and ongoing trials signify a significant shift towards precision medicine in oncology.

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.

As we embrace the era of antibody-drug conjugates (ADCs) in cancer therapy, it’s crucial to understand their impact on ocular health. With ADCs like mirvetuximab offering new hope for ovarian cancer patients, effective partnerships between optometrists and oncologists are key to managing associated ocular adverse events.